Skip to main content

Table 1 Population characteristics and comorbidities in schizophrenia and NAP patients in Stockholm, Sweden in 2012

From: Health care use, drug treatment and comorbidity in patients with schizophrenia or non-affective psychosis in Sweden: a cross-sectional study

 

Study population

Schizophrenia

NAP

  

N

7284

11,485

  

% males

57

49

  

Age (mean, SD)

52.7 (14.4)

49.5 (18.5)

  

Age (median)

53 (43–62)

48 (35–62)

  

1-year prevalence (%, 2012)

RR

95% CI

 Diabetesa

6.9

4.8

1.45

1.28–1.63

 Hypertensiona

7.9

9.7

0.82

0.74–0.90

 Obesity

2.2

2.2

0.97

0.8–1.18

 Substance abusea

7.9

11.7

0.63

0.61–0.74

 Self-harma

0.6

0.9

0.65

0.45–0.93

12-year prevalence (%, 2000–2012)

 Diabetesa

12.5

7.9

1.58

1.44–1.72

 Hypertensiona

17.0

19.3

0.88

0.83–0.94

 Obesitya

9.9

8,0

1.23

1.12–1.35

 Substance abusea

24.8

28.4

0.87

0.83–0.92

 Self-harma

3.5

4.3

0.82

0.70–0.95

  1. Note: If ever (2000–2012) diagnosed with schizophrenia, then considered part of the schizophrenia group only, irrespective of NAP ever diagnosed
  2. astatistically significant difference in RR between the two diagnostic groups (95% CI for RR)